Naxicap Partners acquires Ceres Pharma

Naxicap Partners reached an agreement with Alychlo NV and Mario Debel (co-founder and CEO) to acquire 100% of the shares of Ceres Pharma NV. Simultaneously Mr. Mario Debel will re-invest an important part of his proceeds in Ceres Pharma NV and will continue to lead the company and the current management team into this new phase of growth as CEO and as shareholder. Details of the agreement are not disclosed.

Ceres Pharma NV, a Belgian based pharmaceutical company, has been growing rapidly these last years, both organically and through acquisitions, resulting in a growing number of own brands and a significant increase in geographical reach, namely in Central and Eastern Europe. Both Alychlo NV and Mr. Mario Debel look back with great pride on the growth trajectory realized so far and believe Naxicap is the ideal partner to successfully continue this growth story.

Naxicap Partners will support the company in further expanding its market position, helping it to realize its full potential. The focus will be on the company’s internationalization and further expansion in the BeNeLux, Central Europe, and potentially beyond, and on the development of new sales channels and the scaling of the marketing activities.

About Ceres Pharma

Ceres Pharma is a dynamic and fast growing, Belgian based, pharmaceutical company, founded in 2017 by CEO Mario Debel and Alychlo. It is the ambition of Ceres Pharma to grow through the development of its own product portfolio as well as through acquisitions. Ceres Pharma is active in the development and distribution of drugs, medical devices, biocides, cosmetics and qualitative food supplements in the BeNeLux, and in Central and Eastern Europe.

About Naxicap Partners

As one of the top private equity firms in France, Naxicap Partners – an affiliate of Natixis Investment Managers – has €3.7 billion in assets under management. As a committed, responsible investor, Naxicap Partners builds solid, constructive partnerships with entrepreneurs so that their projects can succeed. The firm has 39 investment professionals spread across five offices in Paris, Lyon, Toulouse, Nantes and Frankfurt. For more information, visit 

About Alychlo

Alychlo NV is the family owned investment company founded by entrepreneur Marc Coucke. Alychlo invests in growth companies and actively supports the management of its portfolio companies enabling them to achieve their growth plans. Current investments, amongst others, include; Fagron, Mithra Pharmaceuticals, Sophia Genetics, La Petite Merveille (Durbuy), Pairi Daiza, SnowWorld, Greenyard, Groep Versluys & Ekopak.